| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
484.12(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.86 - $18.69 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 14.7 |
| Insider 3/6 Months : 15.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the U.S. Food and Drug Administration for the treatment, in combination with Granulocyte-Macrophage Colony-Stimulating Factor of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
268,008 |
558,056 |
762,731 |
| Total Buy Value |
$0 |
$1,869,288 |
$3,530,830 |
$5,499,522 |
| Total People Bought |
0 |
2 |
2 |
3 |
| Total Buy Transactions |
0 |
8 |
14 |
17 |
| Total Shares Sold |
39,644 |
189,644 |
339,644 |
339,644 |
| Total Sell Value |
$515,799 |
$1,516,799 |
$2,312,182 |
$2,312,182 |
| Total People Sold |
3 |
3 |
3 |
3 |
| Total Sell Transactions |
5 |
8 |
10 |
10 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gad Thomas |
President and Chairman |
• • – |
2020-05-12 |
4 |
S |
$39.04 |
$1,951,935 |
I/I |
(50,000) |
778,000 |
|
3% |
|
| Ahmed Mahiuddin |
Sr. VP and CSO |
• – – |
2020-05-12 |
4 |
S |
$39.19 |
$783,776 |
D/D |
(20,000) |
240,000 |
|
3% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-05-01 |
4 |
AS |
$32.35 |
$129,404 |
I/I |
(4,000) |
828,000 |
|
22% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-04-13 |
4 |
AS |
$29.43 |
$117,711 |
I/I |
(4,000) |
832,000 |
|
45% |
|
| Juan Moller San Pedro Claus |
Chief Executive Officer |
• • – |
2020-03-17 |
4 |
B |
$17.22 |
$32,712 |
I/I |
1,900 |
1,900 |
2.66 |
117% |
|
| Gad Thomas |
President and Chairman |
• • – |
2020-03-16 |
4 |
AS |
$18.01 |
$72,041 |
I/I |
(4,000) |
836,000 |
|
111% |
|
| Gad Thomas |
President & Chairman |
• • – |
2020-03-02 |
4 |
AS |
$29.18 |
$116,713 |
I/I |
(4,000) |
840,000 |
|
33% |
|
| Gad Thomas |
President & Chairman |
• • – |
2020-02-18 |
4 |
AS |
$32.78 |
$131,133 |
I/I |
(4,000) |
844,000 |
|
39% |
|
| Gad Thomas |
President & Chairman |
• • – |
2020-02-10 |
4 |
AS |
$33.03 |
$132,121 |
I/I |
(4,000) |
848,000 |
|
46% |
|
| Gad Thomas |
President & Chairman |
• • – |
2020-01-27 |
4 |
AS |
$35.06 |
$140,224 |
I/I |
(4,000) |
852,000 |
|
23% |
|
| Healy James |
Director |
– • – |
2020-01-15 |
4 |
OE |
$11.16 |
$370,002 |
D/D |
25,778 |
25,778 |
|
- |
|
| Ahmed Mahiuddin |
Sr. VP and CSOOfficer |
• – – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
260,000 |
|
27% |
|
| Wg Biotech Aps |
10% Owner |
– – • |
2019-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
498,392 |
5,508,392 |
|
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2019-12-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(201) |
1,030,356 |
|
- |
|
| Wedell-Wedellsborg Johan |
Director |
– • – |
2019-12-30 |
4 |
A |
$0.00 |
$0 |
I/I |
498,392 |
5,508,392 |
|
- |
|
| Wedell-Wedellsborg Johan |
Director |
– • – |
2019-12-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(498,392) |
0 |
|
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2019-12-16 |
4 |
AS |
$31.54 |
$126,176 |
I/I |
(4,000) |
860,000 |
|
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2019-12-13 |
4 |
GD |
$0.00 |
$0 |
I/I |
8,000 |
864,000 |
|
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2019-12-02 |
4 |
AS |
$32.48 |
$129,930 |
I/I |
(4,000) |
872,000 |
|
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2019-11-18 |
4 |
AS |
$28.41 |
$113,658 |
I/I |
(4,000) |
876,000 |
|
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2019-11-04 |
4 |
AS |
$30.10 |
$120,418 |
I/I |
(4,000) |
880,000 |
|
- |
|
| Healy James |
Director |
– • – |
2019-10-30 |
4 |
B |
$28.00 |
$2,520,000 |
I/I |
90,000 |
2,194,278 |
2.1 |
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2019-10-21 |
4 |
AS |
$27.59 |
$110,351 |
I/I |
(4,000) |
884,000 |
|
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2019-10-07 |
4 |
AS |
$25.21 |
$100,848 |
I/I |
(4,000) |
888,000 |
|
- |
|
| Gad Thomas |
President and Chairman |
• • – |
2019-09-16 |
4 |
AS |
$30.59 |
$122,376 |
I/I |
(4,000) |
892,000 |
|
- |
|
255 Records found
|
|
Page 9 of 11 |
|
|
0.09 (0.75%) 
